Wolf-dieter D. Janthur
Aarau, AG, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Extracellular vesicles as prognostic biomarkers: results of a neoadjuvant chemoimmunotherapy clinical trial in stage IIIA (N2) non-small-cell lung cancer (SAKK 16/14).
Journal: Frontiers in immunology
Published: February 09, 2026
Decision-Making in Intrathecal Therapy for Leptomeningeal Disease.
Journal: Oncology
Published: November 27, 2025
First-line immunotherapy ± chemotherapy with or without upfront stereotactic radiotherapy (SRT) in patients with Non-Small cell lung cancer (NSCLC) with asymptomatic brain metastases.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: September 02, 2025
Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment.
Journal: JTO clinical and research reports
Published: April 17, 2024
Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapy.
Journal: Nature communications
Published: March 28, 2024
Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: August 01, 2023
A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: March 14, 2022
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 12, 2021
SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2.
Journal: Cancer immunology, immunotherapy : CII
Published: September 01, 2020
A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: June 12, 2020
Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort.
Journal: Cancer immunology, immunotherapy : CII
Published: October 28, 2019
Image analysis in posttreatment non-small cell lung cancer surveillance: specialists' interpretations reviewed by the thoracic multidisciplinary tumor board.
Journal: Multidisciplinary respiratory medicine
Published: May 13, 2019
Last Updated: 09/26/2026